<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVEPatients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e> have an increased risk of micro- and macrovascular disease, but limited options for antihyperglycemic therapy </plain></SENT>
<SENT sid="1" pm="."><plain>We compared the efficacy and safety of <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> with glipizide in patients with T2DM and moderate-to-severe <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0000083'>renal insufficiency</z:hpo> and inadequate glycemic control.RESEARCH DESIGN AND METHODSPatients (n = 426) were randomized 1:1 to <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> (50 mg every day [q.d.] for moderate <z:hpo ids='HP_0000083'>renal insufficiency</z:hpo> and 25 mg q.d. for severe <z:hpo ids='HP_0000083'>renal insufficiency</z:hpo>) or glipizide (2.5 mg q.d., adjusted based on glycemic control to a 10-mg twice a day maximum dose) </plain></SENT>
<SENT sid="2" pm="."><plain>Randomization was stratified by: 1) renal status (moderate or severe <z:hpo ids='HP_0000083'>renal insufficiency</z:hpo>); 2) history of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e>; and 3) history of <z:hpo ids='HP_0001635'>heart failure</z:hpo>.RESULTSAt week 54, treatment with <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> was noninferior to treatment with glipizide in A1C change from baseline (-0.8 vs. -0.6%; between-group difference -0.11%; 95% CI -0.29 to 0.06) because the upper bound of the 95% CI was less than the prespecified noninferiority margin of 0.4% </plain></SENT>
<SENT sid="3" pm="."><plain>There was a lower incidence of symptomatic <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> adverse events (AEs) with <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> versus glipizide (6.2 and 17.0%, respectively; P = 0.001) and a decrease in body weight with <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> (-0.6 kg) versus an increase (1.2 kg) with glipizide (difference, -1.8 kg; P &lt; 0.001) </plain></SENT>
<SENT sid="4" pm="."><plain>The incidence of gastrointestinal AEs was low with both treatments.CONCLUSIONSIn patients with T2DM and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0000083'>renal insufficiency</z:hpo>, <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> and glipizide provided similar A1C-lowering efficacy </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="40237">Sitagliptin</z:chebi> was generally well-tolerated, with a lower risk of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> and <z:hpo ids='HP_0001824'>weight loss</z:hpo> versus <z:mp ids='MP_0005456'>weight gain</z:mp>, relative to glipizide </plain></SENT>
</text></document>